CRDL vs. FRX, VBV, CUS, AIM, IPA, GPH, APM, GXE, CGC, and MDNA
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Fennec Pharmaceuticals (FRX), VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), Aimia (AIM), ImmunoPrecise Antibodies (IPA), Graphite One (GPH), Andean Precious Metals (APM), Gear Energy (GXE), Canadian Gold (CGC), and Medicenna Therapeutics (MDNA). These companies are all part of the "pharmaceutical products" industry.
Cardiol Therapeutics vs. Its Competitors
Cardiol Therapeutics (TSE:CRDL) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.
Fennec Pharmaceuticals has higher revenue and earnings than Cardiol Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cardiol Therapeutics has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Fennec Pharmaceuticals' return on equity of 29.94% beat Cardiol Therapeutics' return on equity.
0.8% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 14.4% of Fennec Pharmaceuticals shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 1 articles in the media. Cardiol Therapeutics' average media sentiment score of 0.75 beat Fennec Pharmaceuticals' score of 0.29 indicating that Cardiol Therapeutics is being referred to more favorably in the media.
Cardiol Therapeutics has a beta of 0.855752, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 2.479494, indicating that its stock price is 148% more volatile than the S&P 500.
Summary
Fennec Pharmaceuticals beats Cardiol Therapeutics on 10 of the 13 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
This page (TSE:CRDL) was last updated on 10/6/2025 by MarketBeat.com Staff
